Transcriptional differentiation of Trypanosoma brucei during in vitro acquisition of resistance to acoziborole.

ABSTRACT: Subspecies of the protozoan parasite Trypanosoma brucei are the causative agents of Human African Trypanosomiasis (HAT), a debilitating neglected tropical disease prevalent across sub-Saharan Africa. HAT case numbers have steadily decreased since the start of the century, and sustainable elimination of one form of the disease is in sight. However, key to this is the development of novel drugs to combat the disease. Acoziborole is a recently developed benzoxaborole, currently in advanced clinical trials, for treatment of stage 1 and stage 2 HAT. Importantly, acoziborole is orally bioavailable, and curative with one dose. Recent studies have made significant progress in determining the molecular mode of action of acoziborole. However, less is known about the potential mechanisms leading to a

SUBMITTER: Steketee PC 

PROVIDER: S-EPMC8648117 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature